Вірменія - англійська - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - rituximab - concentrate for solution for infusion - 100mg/10ml

Ізраїль - англійська - Ministry of Health

novartis israel ltd - rituximab - concentrate for solution for infusion - rituximab 10 mg / 1 ml - rituximab - rixathon is indicated for the following indications: * non-hodgkin’s lymphoma (nhl): rixathon is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma. rixathon is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy.rixathon is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. rixathon maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll): rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rixathon or patients refractory to previous rixathon plus chemotherapy.* granulomatosis with polyangiitis and microscopic polyangiitis: rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (gpa) (wegener’s granulomatosis (wg) and microscopic polyangiitis (mpa).*pemphigus vulgaris (pv):rixathon is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (pv)

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - rituximab - concentrate and diluent for solution for infusion - 10 mg/ml

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - rituximab - concentrate and diluent for solution for infusion - 10 mg/ml

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

f.hoffmann-la roche ltd., switzerland - rituximab - concentrate and diluent for solution for infusion - 120 mg/ml

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - rituximab - concentrate and diluent for solution for infusion - 119.4 mg

Сінгапур - англійська - HSA (Health Sciences Authority)

roche singapore pte. ltd. - rituximab - injection, solution - rituximab 1400mg

Європейський Союз - англійська - EMA (European Medicines Agency)

pfizer europe ma eeig  - rituximab - leukemia, lymphocytic, chronic, b-cell; arthritis, rheumatoid; microscopic polyangiitis; pemphigus - antineoplastic agents - ruxience is indicated in adults for the following indications:non‑hodgkin’s lymphoma (nhl)ruxience is indicated for the treatment of previously untreated patients with stage iii‑iv follicular lymphoma in combination with chemotherapy.ruxience maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.ruxience monotherapy is indicated for treatment of patients with stage iii‑iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.ruxience is indicated for the treatment of patients with cd20 positive diffuse large b cell non‑hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.chronic lymphocytic leukaemia (cll)ruxience in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory cll. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.rheumatoid arthritisruxience in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease‑modifying anti‑rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies.ruxience has been shown to reduce the rate of progression of joint damage as measured by x‑ray and to improve physical function, when given in combination with methotrexate.granulomatosis with polyangiitis and microscopic polyangiitisruxience, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa).pemphigus vulgarisruxience is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jazeera pharmaceutical industries (jpi), saudi arabia - rituximab - concentrate for solution for infusion - 100 mg

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jazeera pharmaceutical industries (jpi), saudi arabia - rituximab - concentrate for solution for infusion - 500 mg